All In Biotech

Drug Trial Radar · NCT07123155

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Pharmacodynamics, and Preliminary Efficacy of S-606001 as an Add-on to Enzyme Replacement Therapy in Patients With Late-onset Pompe Disease

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Oct 30, 2025

Primary completion

Aug 8, 2027

Study completion Aug 8, 2027

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Aug 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.

Conditions

  • Pompe Disease

Interventions

  • S-606001Drug

    S-606001 administered orally

  • PlaceboDrug

    S-606001 matching placebo administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Percent Forced Vital Capacity (%FVC) at Week 52Time frame: Baseline, Week 52

Locations

28 sites in 9 countries. Site status is shown where the registry gives one.

  • University of California - Irvine Medical Center

    Irvine, California · Recruiting

  • University of Florida (UF) - Gainesville

    Gainesville, Florida · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh School of Medicine

    Pittsburgh, Pennsylvania · Recruiting

  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)

    Fairfax, Virginia · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • HLC Hopital Pierre Wertheimer

    Bron, France · Recruiting

  • AP-HP Hopital Raymond Poincare

    Garches, France · Recruiting

  • Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone

    Marseille, France · Recruiting

  • CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires

    Nice, France · Not yet recruiting

  • Universitaetsklinikum Halle (Saale)

    Halle, Germany · Recruiting

  • SphinCS GmbH

    Höchheim, Germany · Recruiting

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen

    München, Germany · Recruiting

  • A.O.U. Policlinico "G. Martino"

    Messina, Italy · Recruiting

  • AOU Citta della Salute e della Scienza di Torino - Ospedale le Molinette

    Torino, Italy · Recruiting

  • Erasmus MC

    GE Rotterdam, GE Rotterdam, Netherlands · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain · Recruiting

  • Queen Elizabeth Hospital Birmingham

    Birmingham, United Kingdom · Recruiting

  • National Hospital for Neurology & Neurosurgery

    London, United Kingdom · Recruiting

  • Royal Free London NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Royal Victoria Infirmary

    Newcastle upon Tyne, United Kingdom · Recruiting

  • Salford Royal Hospital

    Salford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.